Table 3 Univariable and multivariable analyses of recurrence-free survival of patients with EGFR-Wt lung cancer

Age (≥65)

1.28

0.88–1.87

0.189

Gender (Male)

1.66

1.13–2.47

0.013

Smoking history (+)

1.46

0.93–2.28

0.097

Side (left)

0.81

0.58–1.14

0.228

CEA (> 10 ng/ml)

1.33

0.88–2.00

0.172

CT tumor size (> 4.0 cm)

1.46

1.05–2.03

0.025

Consolidation size (> 4.0 cm)

1.47

1.05–2.05

0.025

GGO (−)

0.90

0.58–1.42

0.665

PET maxSUV (≥6.0)

1.98

1.38–2.83

< 0.001

Surgical procedure (segmentectomy)

1.19

0.64–2.21

0.575

Invasive lepidic adenocarcinoma

0.49

0.22–1.12

0.093

Invasive acinar adenocarcinoma

1.12

0.76–1.63

0.576

Invasive papillary adenocarcinoma

1.24

0.86–1.80

0.244

Invasive mucinous adenocarcinoma

0.58

0.32–1.05

0.072

Invasive solid adenocarcinoma

1.01

0.70–1.45

0.963

Invasive micropapillary adenocarcinoma

1.29

0.32–5.21

0.720

High-grade adenocarcinoma

1.17

0.83–1.64

0.378

Lymphatic vessel invasion (+)

1.84

1.30–2.61

0.001

Blood vessel invasion (+)

1.55

1.10–2.17

0.011

Pleural invasion (+)

1.09

0.78–1.51

0.625

Nodal metastasis (+)

2.90

1.94–4.34

< 0.001

Lepidic component (+)

1.30

0.94–1.80

0.118

Solid component (+)

1.49

1.03–2.16

0.035

Micropapillary component (+)

1.35

0.97–1.87

0.078

Adjuvant chemotherapy (+)

0.73

0.51–1.04

0.081